BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 19486012)

  • 21. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.
    Saegusa M; Machida D; Okayasu I
    Br J Cancer; 2000 Feb; 82(3):571-8. PubMed ID: 10682668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
    Schwartz DR; Kardia SL; Shedden KA; Kuick R; Michailidis G; Taylor JM; Misek DE; Wu R; Zhai Y; Darrah DM; Reed H; Ellenson LH; Giordano TJ; Fearon ER; Hanash SM; Cho KR
    Cancer Res; 2002 Aug; 62(16):4722-9. PubMed ID: 12183431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
    Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
    Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
    Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Risch HA; Puopolo M; Yu H
    Clin Cancer Res; 2006 Feb; 12(4):1208-14. PubMed ID: 16489075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer.
    Li YL; Ye F; Cheng XD; Hu Y; Zhou CY; Lü WG; Xie X
    Eur J Cancer; 2010 Jul; 46(11):2104-18. PubMed ID: 20547056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
    Farley J; Smith LM; Darcy KM; Sobel E; O'Connor D; Henderson B; Morrison LE; Birrer MJ;
    Cancer Res; 2003 Mar; 63(6):1235-41. PubMed ID: 12649182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
    Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
    Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
    Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
    Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coordinately up-regulated genes in ovarian cancer.
    Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
    Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prognostic test for adenocarcinoma of the lung from gene expression profiling data.
    Gordon GJ; Richards WG; Sugarbaker DJ; Jaklitsch MT; Bueno R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):905-10. PubMed ID: 14504202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Chan HY; Cheung AN
    Histopathology; 2011 Dec; 59(6):1163-72. PubMed ID: 22175896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
    Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
    Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
    Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
    Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.